Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Asterand’s Subsidiary BioSeek Extends Collaboration with Merck Serono

Published: Thursday, March 29, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
New three-year deal provides Merck Serono expanded access to BioSeek LLC’s BioMAP® platform.

BioSeek, LLC, a subsidiary of Asterand plc, a pioneer in the application of predictive human biology to drug discovery, has announced that it has signed a new, three-year collaboration agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

The new agreement extends and expands the companies’ previous three-year agreement from 2009.

Under the new research plan, BioSeek will expand the use of its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono.

Jack Davis, Chairman and Interim Chief Executive Officer of Asterand commented: “We highly value our long-standing relationship with Merck Serono. The studies carried out by BioSeek for Merck Serono over the past three years have demonstrated that BioMAP Platform can be used to reliably advance promising molecules through preclinical evaluation. Our scientists have worked closely and productively with the Merck Serono team, and we look forward to our continuing and expanding research with them.”

BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.

Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database.

Assessment with BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals
ToxCast high-throughput screening results using BioSeek’s BioMAP® human primary cell assay systems presented at society of toxicology.
Monday, March 19, 2012
BioSeek and EPA Expand ToxCast™ Contract
BioMAP® Systems technology to profile the biological effects of compounds in a second phase of the agency’s ToxCast™ program.
Monday, July 06, 2009
BioSeek Licenses Two Novel Anti-Inflammatory Peptides
The two peptides, licensed from Amylin Pharmaceuticals, were identified as candidates for development in ongoing research collaboration between the two companies.
Friday, November 14, 2008
Scientific News
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.
Microbe Artwork Shows The Limits Of Antibiotics
An Oxford University research fellow has been creating art using bacteria found in the human gut and harvested from faecal samples.
Urine Excretion From Stem Cell-Derived Kidneys
Researchers report a strategy for enabling urine excretion from kidneys grown from stem cells.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos